Get the Stockscreener App
62.64
1.15%
-0.73
Pre-market:
62.64
Bridgebio Pharma Inc stock is traded at $62.64, with a volume of 2.57M.
It is down -1.15% in the last 24 hours and up +20.60% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$63.37
Open:
$63.88
24h Volume:
2.57M
Relative Volume:
0.98
Market Cap:
$11.97B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-25.99
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+15.44%
1M Performance:
+20.60%
6M Performance:
+63.30%
1Y Performance:
+167.58%
1-Day Range:
$62.06
$64.32
1-Week Range:
$56.74
$69.48
52-Week Range:
$21.72
$69.48
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
62.64 | 12.21B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
New York Life Investment Management LLC Makes New $548,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
What moving averages say about BridgeBio Pharma Inc.Market Risk Analysis & Safe Capital Growth Trade Ideas - newser.com
Cantor Fitzgerald Issues Positive Estimate for BBIO Earnings - MarketBeat
Using Bollinger Bands to evaluate BridgeBio Pharma Inc.2025 Historical Comparison & Risk Managed Trade Strategies - newser.com
What is Leerink Partnrs' Estimate for BBIO FY2025 Earnings? - MarketBeat
Can machine learning forecast BridgeBio Pharma Inc. recoveryJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com
Nisa Investment Advisors LLC Sells 4,667 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
What indicators show strength in BridgeBio Pharma Inc.July 2025 Retail & Verified Momentum Stock Watchlist - newser.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue - MSN
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells $13,206,742.22 in Stock - MarketBeat
Analyzing BridgeBio Pharma Inc. with risk reward ratio charts2025 Market Overview & Community Consensus Stock Picks - newser.com
BridgeBio Pharma director sells $13.2m in BBIO stock By Investing.com - Investing.com Canada
BridgeBio Pharma Inc. (BBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at TD Cowen - MarketBeat
BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts (BBIO) - Seeking Alpha
BBIO: Goldman Sachs Raises Price Target and Maintains Buy Rating - GuruFocus
Raymond James Financial Reaffirms "Outperform" Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Piper Sandler Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Cantor Fitzgerald Increases BridgeBio Pharma (NASDAQ:BBIO) Price Target to $110.00 - MarketBeat
What is HC Wainwright's Estimate for BBIO FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for BBIO FY2026 Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Given Buy Rating at Truist Financial - MarketBeat
Emerald Mutual Fund Advisers Trust Sells 78,609 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript - Insider Monkey
Will BridgeBio Pharma Inc. stock pay special dividendsCPI Data & Risk Controlled Swing Trade Alerts - newser.com
Why retail investors favor BridgeBio Pharma Inc. stockTrade Volume Report & Low Risk High Reward Ideas - newser.com
Piper Sandler Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - Nasdaq
Raymond James Reiterates BridgeBio Pharma (BBIO) Outperform Recommendation - Nasdaq
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells 1,641 Shares of Stock - MarketBeat
BBIO: TD Cowen Raises BridgeBio Pharma Target Price to $95 | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
BridgeBio Pharma Hits New 52-Week High of $69.48, Up 139.38% - Markets Mojo
BridgeBio Pharma (BBIO) Sees Target Price Rise from Raymond James | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap UpHere's Why - MarketBeat
BridgeBio Pharma (BBIO) Sees Analyst Rating Updates and Price Ta - GuruFocus
Piper Sandler Raises Price Target for BBIO to $98 | BBIO Stock N - GuruFocus
BridgeBio Pharma, Inc. $BBIO Position Trimmed by Emerald Advisers LLC - MarketBeat
FY2027 Earnings Estimate for BBIO Issued By Leerink Partnrs - MarketBeat
Truist Securities Boosts BridgeBio Pharma (BBIO) Price Target to $80 | BBIO Stock News - GuruFocus
BridgeBio Pharma stock price target raised to $75 at Leerink on strong Attruby sales - Investing.com
BridgeBio Pharma Reports Strong Q3 2025 Results - TipRanks
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result - MSN
BridgeBio Pharma: Q3 Earnings Snapshot - Stamford Advocate
BridgeBio Pharma (BBIO) Gains Traction with Strong Q3 Results an - GuruFocus
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesWeekly Risk Report & AI Forecast Swing Trade Picks - newser.com
BridgeBio Pharma (MUN:2CL) Price Target Increased by 17.86% to 61.47 - Nasdaq
HC Wainwright & Co. Maintains BridgeBio Pharma (BBIO) Buy Recommendation - Nasdaq
BridgeBio Pharma’s Attruby Launch Drives Revenue Jump In Q3 - Finimize
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):